RecruitingNCT02869529
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
Sponsor
Institut Paoli-Calmettes
Enrollment
4,200 participants
Start Date
Jan 1, 2006
Study Type
OBSERVATIONAL
Conditions
Summary
Database of Institut Paoli-Calmettes patients diagnosed with chronic lymphatic leukemia
Eligibility
Min Age: 18 YearsMax Age: 95 Years
Plain Language Summary
Simplified for easier understanding
This study is building a clinical database at the Institut Paoli-Calmettes cancer center in France to collect information on patients with chronic lymphocytic leukemia (CLL) — a slow-growing type of blood cancer affecting white blood cells — to improve understanding of how the disease progresses and responds to treatment.
**You may be eligible if...**
- You have been diagnosed with chronic lymphocytic leukemia (CLL)
**You may NOT be eligible if...**
- Your diagnosis does not clearly meet standard criteria for CLL; specifically, a Matutes score below 4 suggests a different type of blood cancer and would make you ineligible
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERData collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02869529
Related Trials
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT0596307473 locations
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
NCT062995401 location
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT0594785152 locations
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT0333119886 locations
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
NCT063644231 location